Overview

A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-03-31

Target enrollment:

Participant gender:

Summary

This is a prospective, randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of bremelanotide (BMT) used in combination with tirzepatide therapy in the treatment of obesity in subjects with a BMI ranging from 30.0 to 45.0 kg/m2 (inclusive).

Phase:

PHASE2

Details

Lead Sponsor:

Palatin Technologies, Inc

Treatments:

bremelanotide
Tirzepatide